Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.32 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 5/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL988008 | 0.87 | TSHR (0.71) | TSHRTP53NFKB1CYP2C19CYP2C9 | |
| Cadaverine Tartrate SCHEMBL27906745 | 0.84 | TSHR (0.67) | TSHRTP53NFKB1CYP2C19CYP2C9 | |
| Cadaverine Tartrate SCHEMBL27547121 | 0.84 | TSHR (0.67) | TSHRTP53NFKB1CYP2C19CYP2C9 | |
| Cadaverine Tartrate SCHEMBL4193142 | 0.83 | TSHR (0.43) | TSHRTP53NFKB1CYP2C19TDP1 | |
| Cadaverine Tartrate SCHEMBL9345632 | 0.81 | TSHR (0.62) | TSHRTP53NFKB1CYP2C19CA2 | |
| Cadaverine Tartrate SCHEMBL9345627 | 0.81 | TSHR (0.62) | TSHRTP53NFKB1CYP2C19CA2 | |
| Cadaverine Tartrate SCHEMBL27491776 | 0.81 | TSHR (0.62) | TSHRTP53NFKB1CYP2C19CYP2C9 | |
| Cadaverine Tartrate SCHEMBL9437851 | 0.81 | TSHR (0.62) | TSHRTP53NFKB1CYP2C19CYP2C9 | |
| Cadaverine Tartrate SCHEMBL27906743 | 0.81 | TSHR (0.62) | TSHRTP53NFKB1CYP2C19CYP2C9 | |
| Lactic Acid SCHEMBL5538629 | 0.81 | TP53 (0.69) | TSHRTP53CYP2C19CA2PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065173-A1 | Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy | O'NEILL BRIAN T (US) | 2003-04-03 | — | — | US | claimed |
| WO-2024128359-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF BONE DISEASES | 전남대학교산학협력단 | 2024-06-20 | — | — | WO | disclosed |
| WO-2024128335-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES | 전남대학교산학협력단 | 2024-06-20 | — | — | WO | disclosed |
| CN-106890183-A | A kind of dabigatran etcxilate pharmaceutical composition of high bioavilability | 北京蓝丹医药科技有限公司 | 2017-06-27 | — | — | CN | disclosed |
| EP-2155719-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008147945-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080280981-A1 | Tranexamic acid formulations | XANODYNE PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080146844-A1 | PROCESS FOR PREPARING TOLTERODINE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| US-7355077-B2 | Process for preparing tolterodine | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-04-08 | — | — | US | disclosed |
| US-20060094904-A1 | Reacting methyl 3-(2-benzyloxy-5-methyl phenyl)-3-phenylpropionate with a reducing agent to form 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-05-04 | — | — | US | disclosed |
| WO-1994014438-A1 | HYDANTOIN AND SUCCINIMIDE-SUBSTITUTED DERIVATIVES OF SPIROINDANYLCAMPHORSULFONYL OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994007496-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| WO-1993006092-A1 | PIPERAZINYL (SULFONYL)AMIDE DERIVATIVES OF CAMPHOR AS OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1993-04-01 | — | — | WO | disclosed |
| CN-1070399-A | The amide derivatives oxytocin antagonist that piperizinylcamphorsuoxytocin replaces | MERCK & CO INC (US) | 1993-03-31 | — | — | CN | disclosed |
| US-5137904-A | Useful in the treatment of atherosclerosis and thrombosis | G. D. SEARLE & CO. (US) | 1992-08-11 | — | — | US | disclosed |
| EP-0486280-A2 | Piperidinylcamphorsulfonyl oxytocin antagonists | MERCK & CO. INC. (US) | 1992-05-20 | — | — | EP | disclosed |
| WO-1992007821-A1 | DIASTEREOISOMERS OF BICYCLO-SUBSTITUTED PHENYLACETONITRILE DERIVATIVES | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |
| CN-87107723-A | Agent of dihydropyridine anti-allergy and anti-inflammatory agent | — | 1988-05-18 | — | — | CN | disclosed |
| US-4550105-A | BETA-LACTAMASE INHIBITORS, ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-29 | — | — | US | disclosed |
| US-4547503-A | 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-(oxo-alkyl)-1-piperazinyl]quinoline-3-carboxylic acids and their derivatives, and antibacterial agents containing them | BAYER AKTIENGESELLSCHAFT (DE) | 1985-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146844-A1 | PROCESS FOR PREPARING TOLTERODINE | ADRA2B, ADRB3, ADRB1 | SLC6A2 814/4885ADRB2 5/4885TSHR 81/4885 |
| US-20030065173-A1 | Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy | CHRNA5, CHRNA4, CHRNA10 | SLC6A2 545/4885ADRB2 175/4885TSHR 2084/4885 |
| US-20060094904-A1 | Reacting methyl 3-(2-benzyloxy-5-methyl phenyl)-3-phenylpropionate with a reducing agent to form 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol | ADRB3, UGT1A3, COMT | SLC6A2 500/4885ADRB2 18/4885TSHR 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.